![]() |
市場調査レポート
商品コード
1433292
患者登録ソフトウェアの世界市場:2023-2030年Global Patient Registry Software Market 2023-2030 |
||||||
カスタマイズ可能
|
患者登録ソフトウェアの世界市場:2023-2030年 |
出版日: 2023年12月01日
発行: Orion Market Research
ページ情報: 英文 175 Pages
納期: 2~3営業日
|
世界の患者登録ソフトウェア市場は、予測期間(2023-2030年)にCAGR 8.6%で成長すると予測されます。市場の成長は、世界中の患者中心のケアに起因しています。患者擁護団体の参加に加え、患者報告による転帰測定が含まれることは、患者中心のケアへの傾向の高まりを反映しています。この移行は、患者の視点や経験を記録する患者登録ソフトウェアによって支援されています。米国国立衛生研究所によると、2023年5月現在、患者登録は欧州を中心に幅広い疾患領域をカバーしています。92%の登録が臨床患者を含み、81%がインフォームドコンセントを取得し、76%が収集したデータを保護しました。57%のレジストリが患者報告アウトカム指標を収集し、38%がレジストリの設計プロセス中にPAGと協議し、51%が品質管理の詳細を報告し、46%が維持管理の詳細を報告しました。
レジストリの種類の中では、疾患別レジストリのサブセグメントが世界の患者登録ソフトウェア市場でかなりのシェアを占めると予想されます。BMCによると、2022年4月、疾患レジストリシステムは、同じ疾患を持つ患者の特定の集団に関するデータを収集、分析、報告するために使用される情報システムです。ヘルスケアの評価、罹患率や有病率の推定、ケアの質のモニタリング、フィードバックの提供、疾患の自然経過の観察、臨床安全性のモニタリング、疾患負担、健康アウトカム、コストの評価に使用できます。
患者登録ソフトウェアの世界市場は、北米(米国、カナダ)、欧州(英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域)、アジア太平洋地域(インド、中国、日本、韓国、その他アジア地域)、世界のその他の地域(中東とアフリカ、ラテンアメリカ)を含む地域別にさらに細分化されます。なかでも北米は、慢性疾患の有病率が高いことに加え、同地域で実施される治療手術の件数が増加していることから、世界全体で大きなシェアを占めると予想されます。
全地域の中で、欧州地域は予測期間中にかなりのCAGRで成長すると予測されています。同地域の成長は、同地域における希少疾患のアドボカシーの高まりに起因しています。希少疾患のアドボカシーと認知に重点が置かれるようになったことで、希少疾患に苦しむ患者の満たされていない医療要件が浮き彫りになってきました。患者登録は、患者の経験に関する実際のデータを収集することにより、これらの目的を達成するのに役立ちます。Frontiers誌によると、2022年8月、欧州医薬品庁(EMA)が審査した販売承認申請の26.8%は、いわゆる希少疾病用医薬品でした。希少疾病用医薬品は、生命を脅かすか慢性的に衰弱させるが、欧州連合(EU)における有病率が1万人に5人未満である疾病の治療、予防、診断の促進を目的としたものです。これらの医薬品は、患者集団が小規模で不均一であるため、臨床エビデンスが限られていることが多く、患者登録はこの課題に対処し、規制当局の意思決定を支援するデータを提供する潜在的な方法として認識されています。患者登録は、特定の疾患、状態、または曝露を有する集団の特定の健康転帰に関するデータを収集し、整理する組織化されたシステムです。
Global Patient Registry Software Market Size, Share & Trends Analysis Report by Type of Registry (Disease-Specific Registries, Health Service Registries, and Product Registries), by Type of Software (Stand-Alone Software, and Integrated Software), by Deployment (On-Premises, and Cloud), and by End-User (Hospitals and Health Systems, Government Organizations, and Third Party Administrators (TPAs), Pharmaceutical, Biotechnology, and Medical Device Companies, and Others) Forecast Period (2023-2030)
The global patient registry software market is anticipated to grow at a CAGR of 8.6% during the forecast period (2023-2030). The market's growth is attributed to patient-centered care across the globe. The inclusion of patient-reported outcome measures, in addition to the participation of patient advocacy groups, reflects an increasing tendency toward patient-centered care. This transition is aided by patient registry software, that captures patient viewpoints and experiences. According to the National Institute of Health, in May 2023,patient registries covered a wide range of disease areas, with a focus on Europe. 92% of the registries included clinical patients, 81% obtained informed consent, and 76% protected the collected data. 57% of the registries collected patient-reported outcome measures, 38% consulted PAGs during the registry design process, 51% reported quality management details, and 46% reported maintenance details.
The global patient registry software market is segmented on the type of registry, type of software, deployment, and end user. Based on the type of registry, the market is sub-segmented into disease-specific registries, health service registries, and product registries. Based on the type of software, the market is sub-segmented into stand-alone software, and integrated software. Based on the deployment, the market is sub-segmented into on-premises, and cloud. Further, on the basis of end-user, the market is sub-segmented into hospitals and health systems, government organizations and third-party administrators (TPAs), pharmaceutical, biotechnology, and medical device companies, and others. The government organizations and third party administrators (TPAs) subcategory is expected to capture a significant portion of the market share within the end-user segment. This is attributed to the number of pharmaceutical, biotechnology, and medical device companies has increased, owing essentially to increased demand for pharmaceutical and biotechnology products.
Among the type of registry, the disease-specific registries sub-segment is expected to hold a considerable share of the global patient registry software market. According to the BMC, in April 2022, a disease registry system is an information system used for collecting, analyzing, and reporting data about a certain population of patients with the same condition. It can be used for healthcare evaluation, estimation of incidence and prevalence, monitoring the quality of care, providing feedback, observing the natural course of diseases, monitoring clinical safety, and assessing disease burden, health outcomes, and costs.
The global patient registry software market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the significant prevalence of chronic diseases, in addition to an increase in the number of therapeutic operations conducted in the region.
Among all regions, the Europe regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the rising rare disease advocacy in the region. The growing emphasis on rare disease advocacy and awareness has highlighted to light the unmet medical requirements of patients suffering from orphan diseases. Patient registries help to accomplish these objectives by collecting real-world data on patient experiences. According to the Frontiers, in August 2022, 26.8% of all the marketing authorization applications assessed by the European Medicines Agency (EMA) were for so-called orphan medicinal products, that are meant to treat, prevent or facilitate diagnosis of diseases that are life-threatening or chronically debilitating, but have a prevalence of less than 5 in 10,000 in the European Union (EU). These medicines are often subject to limited clinical evidence owing to their small and heterogeneous patient populations, and patient registries have been identified as a potential way to address this challenge and provide data to support regulatory decision-making. A patient registry is an organized system that collects and organizes data on specified health outcomes for a population with a certain disease, condition or exposure.
The major companies serving the global patient registry software market include Dacima Software, Inc., DSG, Inc., FIGmd Inc., Global Vision Technologies Image Trend Inc., LexisNexis group, IBM Corp., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2022, Quantori, LLC, launched a Registry Science Practice. That focused on the development of registry programs for patients, physicians, and researchers. Registry Science is an emerging area of medical informatics and biostatistics that combines medicine and epidemiology to track long-term health outcomes and improve evidence-based care delivery.